Antibiotic treatment outcomes in community-acquired pneumonia
No Thumbnail Available
Date
2018
Journal Title
Journal ISSN
Volume Title
Abstract
Background/aim: The optimal empiric antibiotic regimen for patients with community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate the clinical cure rate, mortality, and length of stay among patients hospitalized with community-acquired pneumonia in nonintensive care unit (ICU) wards and treated with a β-lactam, β-lactam and macrolide combination, or a fluoroquinolone. Materials and methods: This prospective cohort study was performed using standardized web-based database sheets from January 2009 to September 2013 in nine tertiary care hospitals in Turkey. Results: Six hundred and twenty-one consecutive patients were enrolled. A pathogen was identified in 78 (12.6%) patients. The most frequently isolated bacteria were S. pneumoniae (21.8%) and P. aeruginosa (19.2%). The clinical cure rate and length of stay were not different among patients treated with β-lactam, β-lactam and macrolide combination, and fluoroquinolone. Forty-seven patients (9.2%) died during the hospitalization period. There was no difference in survival among the three treatment groups. Conclusion: In patients admitted to non-ICU hospital wards for CAP, there was no difference in clinical outcomes between β-lactam, β-lactam and macrolide combination, and fluoroquinolone regimens. © TÜBİTAK.
Description
Keywords
Aged , Aged, 80 and over , Anti-Bacterial Agents , beta-Lactams , Community-Acquired Infections , Drug Therapy, Combination , Female , Fluoroquinolones , Hospital Departments , Hospital Mortality , Hospitals , Humans , Length of Stay , Macrolides , Male , Middle Aged , Pneumonia , Prospective Studies , Pseudomonas aeruginosa , Streptococcus pneumoniae , Treatment Outcome , Turkey , albumin , beta lactam antibiotic , beta lactamase inhibitor , ceftriaxone , clarithromycin , levofloxacin , macrolide , moxifloxacin , quinoline derived antiinfective agent , antiinfective agent , beta lactam , macrolide , quinolone derivative , adult , age , aged , antibiotic resistance , antibiotic therapy , Article , cerebrovascular accident , chronic kidney failure , chronic obstructive lung disease , clinical trial , cohort analysis , community acquired pneumonia , CURB-65 score , diabetes mellitus , drug treatment failure , eosinophil count , Escherichia coli , follow up , Haemophilus influenzae , hospital mortality , human , length of stay , lung cancer , major clinical study , male , multicenter study , observational study , oxygen tension , Pneumonia Severity Index , prospective study , Staphylococcus aureus , thorax radiography , treatment outcome , combination drug therapy , community acquired infection , epidemiology , female , growth, development and aging , hospital , hospital department , length of stay , microbiology , middle aged , mortality , pneumonia , Pseudomonas aeruginosa , Streptococcus pneumoniae , turkey (bird) , very elderly